Zoladex
Payments companies reported to CMS as associated with Zoladex. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Zoladex, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Zoladex
These are the largest totals companies reported as associated with Zoladex. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Shari Goldfarb | New York, NY | Hematology & Oncology | $46,718.62 |
| Eric Liu | Denver, CO | Surgical Oncology | $44,893.26 |
| Andrea Stebel | Newport Beach, CA | Hematology & Oncology | $30,052.02 |
| Sandra Swain | Bethesda, MD | Hematology & Oncology | $15,462.94 |
| Joyce O'Shaughnessy | Dallas, TX | Medical Oncology | $12,195.38 |
| Kelly Mccann | Santa Monica, CA | Hematology & Oncology | $11,240.11 |
| Ruta Rao | Chicago, IL | Medical Oncology | $10,568.90 |
| Joyce Steinberg | Northbrook, IL | Hematology & Oncology | $8,453.00 |
| Virginia Borges | Aurora, CO | Medical Oncology | $7,663.53 |
| Seth Wander | Boston, MA | Hematology & Oncology | $7,246.55 |
Prescribed Zoladex?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.